JAK2V617F status of HPCs assayed from PMF CD34+ cells treated with 5azaD/SAHA
| . | PB Granulocytes . | Source of hematopoietic colonies assayed . | |||||
|---|---|---|---|---|---|---|---|
| Primary PMF CD34+ cells . | PMF CD34+ cells treated with cytokines alone . | PMF CD34+ cells trated with cytokines + 5azaD/SAHA . | |||||
| JAK2V617F allele burden (%) . | % JAK2V617F . | % homozygous JAK2V617F . | % JAK2V617F . | % homozygous JAK2V617F . | % JAK2V617F . | % homozygous JAK2V617F . | |
| Patient 1 | 80* | 80 (49/61)† | 70 (43/61) | 91 (42/46) | 17 (8/46) | 84 (31/37) | 11 (4/37) |
| Patient 3 | 35 | 45 (37/83) | 23 (19/83) | 47 (27/58) | 41 (24/58) | 11 (5/44) | 0 (0/44) |
| Patient 6 | 77 | 100 (30/30) | 100 (30/30) | 96 (44/46) | 11 (5/46) | 63 (19/30) | 0 (0/30) |
| Patient 9 | 75 | 88 (22/25) | 0 (0/25) | 77 (10/13) | 77 (10/13) | 43 (3/7) | 43 (3/7) |
| Patient 12 | 37 | 82 (45/55) | 76 (42/55) | 89 (34/38) | 26 (10/38) | 55 (20/35) | 10 (5/35) |
| Patient 13 | 65 | 100 (65/65) | 62 (40/65) | 91 (31/34) | 27 (9/34) | 66 (32/33) | 17 (6/33) |
| Mean | 83‡ | 55§ | 82‡ | 33‖ | 54 | 13 | |
| SD | 8.3 | 15.1 | 7.5 | 9.7 | 10.1 | 6.5 | |
| . | PB Granulocytes . | Source of hematopoietic colonies assayed . | |||||
|---|---|---|---|---|---|---|---|
| Primary PMF CD34+ cells . | PMF CD34+ cells treated with cytokines alone . | PMF CD34+ cells trated with cytokines + 5azaD/SAHA . | |||||
| JAK2V617F allele burden (%) . | % JAK2V617F . | % homozygous JAK2V617F . | % JAK2V617F . | % homozygous JAK2V617F . | % JAK2V617F . | % homozygous JAK2V617F . | |
| Patient 1 | 80* | 80 (49/61)† | 70 (43/61) | 91 (42/46) | 17 (8/46) | 84 (31/37) | 11 (4/37) |
| Patient 3 | 35 | 45 (37/83) | 23 (19/83) | 47 (27/58) | 41 (24/58) | 11 (5/44) | 0 (0/44) |
| Patient 6 | 77 | 100 (30/30) | 100 (30/30) | 96 (44/46) | 11 (5/46) | 63 (19/30) | 0 (0/30) |
| Patient 9 | 75 | 88 (22/25) | 0 (0/25) | 77 (10/13) | 77 (10/13) | 43 (3/7) | 43 (3/7) |
| Patient 12 | 37 | 82 (45/55) | 76 (42/55) | 89 (34/38) | 26 (10/38) | 55 (20/35) | 10 (5/35) |
| Patient 13 | 65 | 100 (65/65) | 62 (40/65) | 91 (31/34) | 27 (9/34) | 66 (32/33) | 17 (6/33) |
| Mean | 83‡ | 55§ | 82‡ | 33‖ | 54 | 13 | |
| SD | 8.3 | 15.1 | 7.5 | 9.7 | 10.1 | 6.5 | |
Indicates the percentage of JAK2V617F allele obtained from granulocytes by real-time quantitative kinetic PCR assay using allelic discrimination method.
Each value represents the percentage of colonies (CFU-GM + BFU-E + CFU-Mixed) exhibiting the JAK2V617F mutation or homozygous JAK2V617F allele. The numbers in parentheses denote the actual number of JAK2V617F-positive or homozygous colonies/the total numbers of colonies (CFU-GM + BFU-E + CFU-Mixed) analyzed.
P < .01 vs the proportion of JAK2V617F+ HPCs assayed from PMF CD34+ cells treated with 5azaD/SAHA.
P = .09,
P < .05 vs the proportion of JAK2V617F homozygous HPCs assayed from PMF CD34+ cells treated with 5azaD/SAHA.